M. de Boer

Hillege, L. E., Barnett, D. J. M., Ziemons, J., Aarnoutse, R., de Vos-Geelen, J., van Geel, R., de Boer, M., van Riet, Y. E. A., Vincent, J., Penders, J., & Smidt, M. L. (2025). The gut microbiota during tamoxifen therapy in patients with breast cancer. Scientific Reports, 15(1), Article 7874. https://doi.org/10.1038/s41598-025-91734-1

Vrancken Peeters, N. J. M. C., Kerklaan, R., Vlooswijk, C., Bijlsma, R. M., Kaal, S. E. J., Tromp, J. M., Bos, M. E. M. M., van der Hulle, T., de Boer, M., Nuver, J., Kouwenhoven, M. C. M., van der Graaf, W. T. A., & Husson, O. (2025). Long-term health-related quality of life among adolescent and young adult breast cancer survivors. Quality of Life Research, Article 100255. https://doi.org/10.1007/s11136-025-03914-1

Guchelaar, N. A. D., Mathijssen, R. H. J., de Boer, M., van Bekkum, M. L., Heijns, J. B., Vriens, B. E. P. J., van Rosmalen, M. M., Kessels, L. W., Hamming, L., Beelen, K. J., Nieboer, P., van den Berg, S. M., Hoop, E. O. D., Bijlsma, R. M., Bos, M. E. M. M., & Dutch Breast Cancer Research Group (BOOG) (2025). Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial. EClinicalMedicine, 80, Article 103065. https://doi.org/10.1016/j.eclinm.2024.103065

Harbeck, N., Ciruelos, E., Jerusalem, G., Müller, V., Niikura, N., Viale, G., Bartsch, R., Kurzeder, C., Higgins, M. J., Connolly, R. M., Baron-Hay, S., Gión, M., Guarneri, V., Bianchini, G., Wildiers, H., Escrivá-de-Romaní, S., Prahladan, M., Bridge, H., Kuptsova-Clarkson, N., ... DESTINY-Breast12 study group (2024). Publisher Correction: Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial(Nature Medicine, 10.1038/s41591-024-03261-7). Nature Medicine, 30(12), Article 3780. https://doi.org/10.1038/s41591-024-03349-0

Harbeck, N., Ciruelos, E., Jerusalem, G., Mueller, V., Niikura, N., Viale, G., Bartsch, R., Kurzeder, C., Higgins, M. J., Connolly, R. M., Baron-Hay, S., Gion, M., Guarneri, V., Bianchini, G., Wildiers, H., Escriva-de-Romani, S., Prahladan, M., Bridge, H., Kuptsova-Clarkson, N., ... de Boer, M. (2024). Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nature Medicine, 30(12), 3717–3727. Article 967. https://doi.org/10.1038/s41591-024-03261-7

van Nijnatten, T. J. A., de Mooij, C. M., Mitea, C., Houwers, J., de Boer, M., Smidt, M. L., Mottaghy, F. M., & Wildberger, J. E. (2024). [18F]FDG whole-body PET-MR including an integrated breast MR protocol for locoregional and distant staging in breast cancer patients-a feasibility study. Insights into Imaging, 15(1), Article 243. https://doi.org/10.1186/s13244-024-01830-5

Geurts, S. M. E., Ibragimova, K. I. E., Ding, N., Meegdes, M., Erdkamp, F., Heijns, J. B., Tol, J., Vriens, B. E. P. J., Dercksen, M. W., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L., Peters, N. A. J. B., van de Wouw, A. J., Maaskant, S. A. J. G., Teeuwen-Dedroog, N. J. A., van Nijnatten, T. J. A., de Boer, M., & Tjan-Heijnen, V. C. G. (2024). Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+?metastatic breast cancer: an analysis of the SONABRE registry. Breast Cancer Research and Treatment, 205(2), 287-302. https://doi.org/10.1007/s10549-023-07235-0

van Roozendaal, L. M., Vane, M. L. G., Colier, E., Strobbe, L. J. A., de Boer, M., Sonke, G., Van Maaren, M. C., & Smidt, M. L. (2024). Gene expression profiles in clinically T1-2N0 ER+HER2- breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed. Breast Cancer Research and Treatment, 203(1), 103-110. https://doi.org/10.1007/s10549-023-07128-2

Voorwerk, L., Isaeva, O. I. I., Horlings, H. M. M., Balduzzi, S., Chelushkin, M., Bakker, N. A. M., Champanhet, E., Garner, H., Sikorska, K., Loo, C. E. E., Kemper, I., Mandjes, I. A. M., de Maaker, M., van Geel, J. J. L., Boers, J., de Boer, M., Salgado, R., van Dongen, M. G. J., Sonke, G. S. S., ... Kok, M. (2023). PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial. Nature Cancer, 4(4), 535–549. https://doi.org/10.1038/s43018-023-00542-x

Rugo, H. S., Im, S.-A., Cardoso, F., Cortes, J., Curigliano, G., Musolino, A., Pegram, M. D., Bachelot, T., Wright, G. S., Saura, C., Escrivá-de-Romaní, S., De Laurentiis, M., Schwartz, G. N., Pluard, T. J., Ricci, F., Gwin, W. R., Levy, C., Brown-Glaberman, U., Ferrero, J.-M., ... SOPHIA Study Group (2023). Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. Journal of Clinical Oncology, 41(2), 198-205. https://doi.org/10.1200/JCO.21.02937